Morepen Laboratories (NSE:MOREPENLAB) Piotroski F-Score: 4 (As of Jun. 27, 2026) — 33% Below Median


NSE:MOREPENLAB Morepen Laboratories Ltd NSE:MOREPENLAB
74 GF Score
Price ₹53.16
GF Value ₹49.82
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Morepen Laboratories Piotroski F-Score?

Morepen Laboratories NSE:MOREPENLAB +2.00% 74 Piotroski F-Score is 4 as of Jun. 27, 2026, which is 33% below its 10-year median of 6.00. GuruFocus rates NSE:MOREPENLAB with a GF Score™ of 74/100 and a GF Value™ of ₹49.82 (Fairly Valued). The stock has 5 warning signs investors should review. Among 981 Drug Manufacturers companies, Morepen Laboratories ranks worse than 61.06% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Morepen Laboratories has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Morepen Laboratories's Piotroski F-Score or its related term are showing as below:

NSE:MOREPENLAB' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 9
Current: 4

During the past 13 years, the highest Piotroski F-Score of Morepen Laboratories was 9. The lowest was 3. And the median was 6.

Morepen Laboratories  (NSE:MOREPENLAB) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Morepen Laboratories Piotroski F-Score Related Terms


Morepen Laboratories Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Morepen Laboratories's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Morepen Laboratories Piotroski F-Score Chart

Morepen Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 5.00 5.00 5.00 4.00

Morepen Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 0.00 0.00 0.00 4.00

NSE:MOREPENLAB vs ZTS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Morepen Laboratories Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Morepen Laboratories's Piotroski F-Score falls into.


NSE:MOREPENLAB
74GF Score
Morepen Laboratories Ltd NSE:MOREPENLAB
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was ₹949 Mil.
Cash Flow from Operations was ₹326 Mil.
Revenue was ₹18,057 Mil.
Gross Profit was ₹6,823 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was (17780.993 + 19361.201) / 2 = ₹18571.097 Mil.
Total Assets at the begining of this year (Mar25) was ₹17,781 Mil.
Long-Term Debt & Capital Lease Obligation was ₹1,379 Mil.
Total Current Assets was ₹11,636 Mil.
Total Current Liabilities was ₹4,903 Mil.
Net Income was ₹1,180 Mil.

Revenue was ₹18,116 Mil.
Gross Profit was ₹6,523 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was (12932.051 + 17780.993) / 2 = ₹15356.522 Mil.
Total Assets at the begining of last year (Mar24) was ₹12,932 Mil.
Long-Term Debt & Capital Lease Obligation was ₹392 Mil.
Total Current Assets was ₹11,594 Mil.
Total Current Liabilities was ₹5,007 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Morepen Laboratories's current Net Income (TTM) was 949. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Morepen Laboratories's current Cash Flow from Operations (TTM) was 326. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=948.768/17780.993
=0.05335855

ROA (Last Year)=Net Income/Total Assets (Mar24)
=1180.204/12932.051
=0.09126194

Morepen Laboratories's return on assets of this year was 0.05335855. Morepen Laboratories's return on assets of last year was 0.09126194. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Morepen Laboratories's current Net Income (TTM) was 949. Morepen Laboratories's current Cash Flow from Operations (TTM) was 326. ==> 326 <= 949 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=1378.614/18571.097
=0.07423439

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=392.422/15356.522
=0.02555409

Morepen Laboratories's gearing of this year was 0.07423439. Morepen Laboratories's gearing of last year was 0.02555409. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=11636.141/4903.021
=2.37325947

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=11593.717/5006.536
=2.3157163

Morepen Laboratories's current ratio of this year was 2.37325947. Morepen Laboratories's current ratio of last year was 2.3157163. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Morepen Laboratories's number of shares in issue this year was 548.421. Morepen Laboratories's number of shares in issue last year was 536.456. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=6822.75/18056.915
=0.37784694

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=6522.686/18115.758
=0.36005592

Morepen Laboratories's gross margin of this year was 0.37784694. Morepen Laboratories's gross margin of last year was 0.36005592. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=18056.915/17780.993
=1.01551781

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=18115.758/12932.051
=1.40084183

Morepen Laboratories's asset turnover of this year was 1.01551781. Morepen Laboratories's asset turnover of last year was 1.40084183. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+0+1+0+1+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Morepen Laboratories has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Morepen Laboratories (NSE:MOREPENLAB) has a Piotroski F-Score of 4 as of Jun. 27, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Morepen Laboratories and its competitors. This is 33% below median its historical median of 6.00. Over the past decade, Morepen Laboratories' Piotroski F-Score has ranged from 3.00 to 9.00. According to the industry distribution chart, Morepen Laboratories ranks #599 out of 981 companies in the Drug Manufacturers industry, placing it in the top 61.1%.
Is Morepen Laboratories' Piotroski F-Score too high?
Morepen Laboratories' current Piotroski F-Score of 4 is 33% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Morepen Laboratories' value of 4 is 20% below this industry median. Based on the distribution chart, Morepen Laboratories ranks #599 out of 981 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Morepen Laboratories has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Morepen Laboratories' Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Morepen Laboratories ranks #599 out of 981 companies for Piotroski F-Score. This places Morepen Laboratories in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Morepen Laboratories' value of 4 is 20% below this benchmark. Historically, Morepen Laboratories' own Piotroski F-Score has ranged from 3.00 to 9.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Morepen Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Morepen Laboratories's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Morepen Laboratories and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Morepen Laboratories's current Piotroski F-Score is 4, which is 33% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morepen Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Morepen Laboratories (NSE:MOREPENLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹49.82, compared to a current price of ₹53.16 — trading 6.7% above its estimated fair value. The current Piotroski F-Score is 4, which is 33% below median its 10-year median of 6.00 and 20% below the Drug Manufacturers industry median of 5.00. Morepen Laboratories' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Morepen Laboratories (NSE:MOREPENLAB), the current Piotroski F-Score is 4 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued. The current stock price of ₹53.16 is trading 6.7% above its estimated GF Value™ of ₹49.82. GuruFocus considers Morepen Laboratories to be Fairly Valued.

Key valuation signals for NSE:MOREPENLAB:

  • Piotroski F-Score: 4 (33% below median its 10-year median of 6.00)
  • GF Value™: ₹49.82 vs. price of ₹53.16 (6.7% above fair value)
  • GF Score™: 74/100 with 5 warning signs
  • Industry Position: 20% below the Drug Manufacturers median (#599 of 981)

No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Morepen Laboratories Business Description

Other Exchanges 500288:India
Address Udyog Vihar-III, Sector-20, 2nd Floor, Tower C, DLF Cyber Park, Gurugram, HR, IND, 122016
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
74GF Score

Get the complete analysis for NSE:MOREPENLAB

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹53.16
Price
₹49.82
GF Value